Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
10.01.2022 Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections | Atriva Therapeutics | FDA ODD
Eva Bauer Raimund Gabriel Oliver Planz Rainer Lichtenberger Mc Services Drug Administration Atriva Therapeutics
Source: dgap.de